drugset / Trial / NCT06027554
The Mito-Frail Trial: Effects of MitoQ on Vasodilation, Mobility and Cognitive Performance in Frail Older Adults
Phase 2
Recruiting
60 enrolled
UConn Health
National Institute on Aging (NIA) · collabUniversity of Connecticut · collab
RandomizedCrossoverTriple-blindTreatment
Summary
The goal of this clinical trial is to test the effects of MitoQ supplementation in older adults and frail older adults with physical dysfunction and/or cognitive dysfunction. The main question\[s\] it aims to answer are: * To compare vascular function, oxidative stress levels, and physical and cognitive function among older adults and frail older adults with physical and cognitive dysfunction * To determine whether MitoQ supplementation has the potential to improve vascular function in central and cerebral vessels * To determine whether MitoQ supplementation can enhance physical and cognitive capabilities.
Timeline
- Start
- 2024-10-07
- Primary completion
- 2027-03-01
- Completion
- 2028-02-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MitoQ | Small molecule | 20 mg | — |